Surveillance Recommendations for Children with Overgrowth Syndromes and Predisposition to Wilms Tumors and Hepatoblastoma

Jennifer M Kalish, Leslie Doros, Lee J Helman, Raoul C Hennekam, Roland P Kuiper, Saskia M Maas, Eamonn R Maher, Kim E Nichols, Sharon E Plon, Christopher C Porter, Surya Rednam, Kris Ann P Schultz, Lisa J States, Gail E Tomlinson, Kristin Zelley, Todd E Druley, Jennifer M Kalish, Leslie Doros, Lee J Helman, Raoul C Hennekam, Roland P Kuiper, Saskia M Maas, Eamonn R Maher, Kim E Nichols, Sharon E Plon, Christopher C Porter, Surya Rednam, Kris Ann P Schultz, Lisa J States, Gail E Tomlinson, Kristin Zelley, Todd E Druley

Abstract

A number of genetic syndromes have been linked to increased risk for Wilms tumor (WT), hepatoblastoma (HB), and other embryonal tumors. Here, we outline these rare syndromes with at least a 1% risk to develop these tumors and recommend uniform tumor screening recommendations for North America. Specifically, for syndromes with increased risk for WT, we recommend renal ultrasounds every 3 months from birth (or the time of diagnosis) through the seventh birthday. For HB, we recommend screening with full abdominal ultrasound and alpha-fetoprotein serum measurements every 3 months from birth (or the time of diagnosis) through the fourth birthday. We recommend that when possible, these patients be evaluated and monitored by cancer predisposition specialists. At this time, these recommendations are not based on the differential risk between different genetic or epigenetic causes for each syndrome, which some European centers have implemented. This differentiated approach largely represents distinct practice environments between the United States and Europe, and these guidelines are designed to be a broad framework within which physicians and families can work together to implement specific screening. Further study is expected to lead to modifications of these recommendations. Clin Cancer Res; 23(13); e115-e22. ©2017 AACRSee all articles in the online-only CCR Pediatric Oncology Series.

Conflict of interest statement

Conflicts of interest: Baylor College of Medicine (BCM) and Miraca Holdings Inc. have formed a joint venture with shared ownership and governance of the Baylor Genetics Laboratory. Dr. Plon serves on the Scientific Advisory board of the Baylor Genetics Laboratory. The other authors declare no potential conflicts of interest

©2017 American Association for Cancer Research.

References

    1. Dumoucel S, Gauthier-Villars M, Stoppa-Lyonnet D, Parisot P, Brisse H, Philippe-Chomette P, et al. Malformations, genetic abnormalities, and Wilms tumor. Pediatr Blood Cancer. 2014;61(1):140–4. doi: 10.1002/pbc.24709.
    1. Mussa A, Di Candia S, Russo S, Catania S, De Pellegrin M, Di Luzio L, et al. Recommendations of the Scientific Committee of the Italian Beckwith-Wiedemann Syndrome Association on the diagnosis, management and follow-up of the syndrome. European journal of medical genetics. 2016;59(1):52–64. doi: 10.1016/j.ejmg.2015.11.008.
    1. Maas SM, Vansenne F, Kadouch DJM, Ibrahim A, Bliek J, Hopman S, et al. Phenotype, cancer risk, and surveillance in Beckwith–Wiedemann syndrome depending on molecular genetic subgroups. American Journal of Medical Genetics Part A. 2016;170(9):2248–60. doi: 10.1002/ajmg.a.37801.
    1. Ibrahim A, Kirby G, Hardy C, Dias RP, Tee L, Lim D, et al. Methylation analysis and diagnostics of Beckwith-Wiedemann syndrome in 1,000 subjects. Clin Epigenetics. 2014;6(1):11. doi: 10.1186/1868-7083-6-11.
    1. Mussa A, Molinatto C, Baldassarre G, Riberi E, Russo S, Larizza L, et al. Cancer Risk in Beckwith-Wiedemann Syndrome: A Systematic Review and Meta-Analysis Outlining a Novel (Epi)Genotype Specific Histotype Targeted Screening Protocol. The Journal of pediatrics. 2016;176:142–9. e1. doi: 10.1016/j.jpeds.2016.05.038.
    1. Kalish JM, Deardorff MA. Tumor screening in Beckwith-Wiedemann syndrome-To screen or not to screen? Am J Med Genet A. 2016;170(9):2261–4. doi: 10.1002/ajmg.a.37881.
    1. Duffy KA, Deardorff MA, Kalish JM. The Utility of Alpha-Fetoprotein Screening in Beckwith-Wiedemann Syndrome. Am J Med Genet A. 2016 in press.
    1. Mussa A, Ferrero GB. Serum alpha-fetoprotein screening for hepatoblastoma in Beckwith-Wiedemann syndrome. Am J Med Genet A. 2016 in press.
    1. Bohring A, Oudesluijs GG, Grange DK, Zampino G, Thierry P. New cases of Bohring-Opitz syndrome, update, and critical review of the literature. American Journal of Medical Genetics Part A. 2006;140A(12):1257–63. doi: 10.1002/ajmg.a.31265.
    1. Hastings R, Cobben JM, Gillessen-Kaesbach G, Goodship J, Hove H, Kjaergaard S, et al. Bohring-Opitz (Oberklaid-Danks) syndrome: clinical study, review of the literature, and discussion of possible pathogenesis. European Journal of Human Genetics. 2011;19(5):513–9. doi: 10.1038/ejhg.2010.234.
    1. Bohring A, Silengo M, Lerone M, Superneau DW, Spaich C, Braddock SR, et al. Severe end of Opitz trigonocephaly (C) syndrome or new syndrome? American Journal of Medical Genetics. 1999;85(5):438–46. doi: 10.1002/(SICI)1096-8628(19990827)85:5<438::AID-AJMG2>;2-A.
    1. Hoischen A, Bon BWv, Roiguez-Santiago B, Gilissen CFHA, Vissers LELM, Vries PFd, et al. De novo nonsense mutations in ASXL1 cause Bohring-Opitz syndrome. Nature Genetics. 2011;43(8):729–31. doi: 10.1038/ng.868.
    1. Dangiolo SB, Wilson A, Jobanputra V, Anyane-Yeboa K. Bohring-Opitz syndrome (BOS) with a newASXL1pathogenic variant: Review of the most prevalent molecular and phenotypic features of the syndrome. American Journal of Medical Genetics Part A. 2015;167(12):3161–6. doi: 10.1002/ajmg.a.37342.
    1. Russell B, Johnston JJ, Biesecker LG, Kramer N, Pickart A, Rhead W, et al. Clinical management of patients with ASXL1 mutations and Bohring–Opitz syndrome, emphasizing the need for Wilms tumor surveillance. American Journal of Medical Genetics Part A. 2015;167(9):2122–31. doi: 10.1002/ajmg.a.37131.
    1. Aravind L, Iyer LM. The HARE-HTH and associated domains: novel modules in the coordination of epigenetic DNA and protein modifications. Cell Cycle. 2012;11(1):119–31. doi: 10.4161/cc.11.1.18475.
    1. Wang J, Li Z, He Y, Pan F, Chen S, Rhodes S, et al. Loss of Asxl1 leads to myelodysplastic syndrome-like disease in mice. Blood. 2014;123(4):541–53. doi: 10.1182/blood-2013-05-500272.
    1. Abdel-Wahab O, Adli M, LaFave LM, Gao J, Hricik T, Shih AH, et al. ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression. Cancer cell. 2012;22(2):180–93. doi: 10.1016/j.ccr.2012.06.032.
    1. Russell B, Graham JJM. Expanding our knowledge of conditions associated with the ASXL gene family. Genome medicine. 2013;5(2):16.
    1. Karlberg S, Lipsanen-Nyman M, Lassus H, Kallijärvi J, Lehesjoki A-E, Butzow R. Gynecological tumors in Mulibrey nanism and role for RING finger protein TRIM37 in the pathogenesis of ovarian fibrothecomas. Modern Pathology. 2009;22(4):570–8. doi: 10.1038/modpathol.2009.13.
    1. Karlberg N, Karlberg S, Karikoski R, Mikkola S, Lipsanen-Nyman M, Jalanko H. High frequency of tumours in Mulibrey nanism. The Journal of pathology. 2009;218(2):163–71. doi: 10.1002/path.2538.
    1. Neri G, Martini-Neri ME, Katz BE, Opitz JM. The Perlman syndrome: familial renal dysplasia with Wilms tumor, fetal gigantism and multiple congenital anomalies. American journal of medical genetics. 1984;19(1):195–207. doi: 10.1002/ajmg.1320190120.
    1. Perlman M, Goldberg GM, Bar-Ziv J, Danovitch G. Renal hamartomas and nephroblastomatosis with fetal gigantism: a familial syndrome. The Journal of pediatrics. 1973;83(3):414.
    1. Perlman M, Levin M, Wittels B. Syndrome of fetal gigantism, renal hamartomas, and nephroblastomatosis with Wilms’ tumor. Cancer. 1975;35(4):1212–7. doi: 10.1002/1097-0142(197504)35:4<1212::AID-CNCR2820350427>;2-2.
    1. Perlman EJ. Pediatric renal tumors: practical updates for the pathologist. Pediatr Dev Pathol. 2005;8(3):320–38. doi: 10.1007/s10024-005-1156-7.
    1. Alessandri JL, Cuillier F, Ramful D, Ernould S, Robin S, de Napoli-Cocci S, et al. Perlman syndrome: report, prenatal findings and review. American journal of medical genetics Part A. 2008;146A(19):2532–7. doi: 10.1002/ajmg.a.32391.
    1. Faehnle CR, Walleshauser J, Joshua-Tor L. Mechanism of Dis3l2 substrate recognition in the Lin28-let-7 pathway. Nature. 2014;514(7521):252–6. doi: 10.1038/nature13553.
    1. Astuti D, Morris MR, Cooper WN, Staals RHJ, Wake NC, Fews GA, et al. Germline mutations in dis3l2 cause the perlman syndrome of overgrowth and wilms tumor susceptibility. Nature Genetics. 2012;44(3):277–84. doi: 10.1038/ng.1071.
    1. Lapunzina P. Risk of tumorigenesis in overgrowth syndromes: a comprehensive review. Am J Med Genet C Semin Med Genet. 2005;137C(1):53–71. doi: 10.1002/ajmg.c.30064.
    1. Pilia G, Hughes-Benzie RM, MacKenzie A, Baybayan P, Chen EY, Huber R, et al. Mutations in GPC3, a glypican gene, cause the Simpson-Golabi-Behmel overgrowth syndrome. Nat Genet. 1996;12(3):241–7. doi: 10.1038/ng0396-241.
    1. Veugelers M, Vermeesch J, Watanabe K, Yamaguchi Y, Marynen P, David G. GPC4, the gene for human K-glypican, flanks GPC3 on xq26: deletion of the GPC3-GPC4 gene cluster in one family with Simpson-Golabi-Behmel syndrome. Genomics. 1998;53(1):1–11. doi: 10.1006/geno.1998.5465.
    1. Vaisfeld A, Pomponi MG, Pietrobono R, Tabolacci E, Neri G. Simpson-Golabi-Behmel syndrome in a female: A case report and an unsolved issue. Am J Med Genet A. 2016 doi: 10.1002/ajmg.a.38003.
    1. Punnett HH. Simpson-Golabi-Behmel syndrome (SGBS) in a female with an X-autosome translocation. Am J Med Genet. 1994;50(4):391–3. doi: 10.1002/ajmg.1320500424.
    1. Li M, Shuman C, Fei YL, Cutiongco E, Bender HA, Stevens C, et al. GPC3 mutation analysis in a spectrum of patients with overgrowth expands the phenotype of Simpson-Golabi-Behmel syndrome. Am J Med Genet. 2001;102(2):161–8.
    1. Lapunzina P, Badia I, Galoppo C, De Matteo E, Silberman P, Tello A, et al. A patient with Simpson-Golabi-Behmel syndrome and hepatocellular carcinoma. J Med Genet. 1998;35(2):153–6.
    1. Buonuomo PS, Ruggiero A, Vasta I, Attina G, Riccardi R, Zampino G. Second case of hepatoblastoma in a young patient with Simpson-Golabi-Behmel syndrome. Pediatr Hematol Oncol. 2005;22(7):623–8. doi: 10.1080/08880010500198988.
    1. Mateos ME, Beyer K, Lopez-Laso E, Siles JL, Perez-Navero JL, Pena MJ, et al. Simpson-Golabi-Behmel syndrome type 1 and hepatoblastoma in a patient with a novel exon 2–4 duplication of the GPC3 gene. Am J Med Genet A. 2013;161A(5):1091–5. doi: 10.1002/ajmg.a.35738.
    1. Kosaki R, Takenouchi T, Takeda N, Kagami M, Nakabayashi K, Hata K, et al. Somatic CTNNB1 mutation in hepatoblastoma from a patient with Simpson-Golabi-Behmel syndrome and germline GPC3 mutation. Am J Med Genet A. 2014;164A(4):993–7. doi: 10.1002/ajmg.a.36364.
    1. Hughes-Benzie RM, Hunter AG, Allanson JE, Mackenzie AE. Simpson-Golabi-Behmel syndrome associated with renal dysplasia and embryonal tumor: localization of the gene to Xqcen-q21. Am J Med Genet. 1992;43(1–2):428–35.
    1. Thomas M, Enciso V, Stratton R, Shah S, Winder T, Tayeh M, et al. Metastatic medulloblastoma in an adolescent with Simpson-Golabi-Behmel syndrome. Am J Med Genet A. 2012;158A(10):2534–6. doi: 10.1002/ajmg.a.35284.
    1. Scott RH, Walker L, Olsen ØE, Levitt G, Kenney I, Maher E, et al. Surveillance for Wilms tumour in at-risk children: pragmatic recommendations for best practice. Archives of disease in childhood. 2006;91(12):995–9. doi: 10.1136/adc.2006.101295.
    1. Imataka G, Suzumura H, Arisaka O. Clinical features and survival in individuals with trisome 18: A retrospective one-center study of 44 patients who received intensive care treatments. Molecular Medicine Reports. 2016:13.
    1. Cereda A, Carey JC. The trisomy 18 syndrome. Orphanet Journal of Rare Diseases. 2012;7(81)
    1. Satge D, Nishi M, Sirvent N, Vekemans M. A Tumor Profile in Edwards syndrome (trisomy 18) American Journal of Medical Genetics Part C (Seminars in Medical Genetics) 2016;172(3)
    1. Uekusa S, Sugito K, Kawashima H, Yoshizawa S, Furuya T, Ohasi K, et al. Successful treatment for hepatoblastoma in a 1-year-old boy with trisomy 18. Pediatrics International. 2012;54(3):428–30.
    1. Faucette K, Carey J. Trisomy 18 and Wilms’ tumor- is there an association? Clin Res. 1991;39(96)
    1. Carey J, Faucette K, Schimke R. Increased risk of Wilms tumor in children with trisomy 18: The evidence and recommendations for a surveillance protocol. Proc Greenwood Genet Cent. 2002;21(74A)
    1. Carey J, Barnes A. Wilms Tumor and Trisomy 18: Is there an Association. American Journal of Medical Genetics Part C. 2016;172C:307–8.
    1. Little M, Wells C. A clinical overview of WT1 gene mutations. Human mutation. 1997;9(3):209–25. doi: 10.1002/(SICI)1098-1004(1997)9:3<209::AID-HUMU2>;2-2.
    1. Parenti R, Salvatorelli L, Musumeci G, Parenti C, Giorlandino A, Motta F, et al. Wilms’ tumor 1 (WT1) protein expression in human developing tissues. Acta Histochem. 2015;117(4–5):386–96. doi: 10.1016/j.acthis.2015.03.009.
    1. Koziell A, Charmandari E, Hindmarsh P, Rees L, Scambler P, Brook C. Frasier syndrome, part of the Denys Drash continuum or simply at WT1 gene associated disorder of intersex and nephropathy. Clin Endocrinol. 2000;52(4):519–24.
    1. Fischbach BV, Trout KL, Lewis J, Luis CA, Sika M. WAGR syndrome: a clinical review of 54 cases. Pediatrics. 2005;116(4):984–8. doi: 10.1542/peds.2004-0467.
    1. Royer-Pokora B, Beier M, Henzler M, Alam R, Schumacher V, Weirich A, et al. Twenty-four new cases of WT1 germline mutations and review of the literature: Genotype/phenotype correlations for Wilms tumor development. American Journal of Medical Genetics Part A. 2004;127A(3):249–57. doi: 10.1002/ajmg.a.30015.
    1. Scott R, Stiller C, Walker L, Rahman N. Syndromes and constitutional chromosomal abnormalities associated with Wilms tumour. J Med Genet. 2006;43(9):705–15.
    1. Reddy J, Licht J. The WT1 Wilms’ tumor suppressor gene: How much do we really know? Biochimica et Biophysica Acta. 1996;1287:1–28.
    1. Segers H, Kersseboom R, Alders M, Pieters R, Wagner A, van den Heuvel-Eibrink MM. Frequency of WT1 and 11p15 constitutional aberrations and phenotypic correlation in childhood Wilms tumour patients. European journal of cancer (Oxford, England : 1990) 2012;48(17):3249. doi: 10.1016/j.ejca.2012.06.008.
    1. Lehnhardt A, Karnatz C, Ahlenstiel-Grunow T, Benz K, Benz MR, Budde K, et al. Clinical and molecular characterization of patients with heterozygous mutations in wilms tumor suppressor gene 1. Clinical journal of the American Society of Nephrology : CJASN. 2015;10(5):825. doi: 10.2215/CJN.10141014.
    1. Lipska BS, Ranchin B, Iatropoulos P, Gellermann J, Melk A, Ozaltin F, et al. Genotype-phenotype associations in WT1 glomerulopathy. Kidney international. 2014;85(5):1169–78. doi: 10.1038/ki.2013.519.
    1. Ezaki J, Hashimoto K, Asano T, Kanda S, Akioka Y, Hattori M, et al. Gonadal tumor in Frasier syndrome: a review and classification. Cancer prevention research. 2015;8(4):271.
    1. Mueller RF. The Denys-Drash syndrome. Journal of medical genetics. 1994;31(6):471–7. doi: 10.1136/jmg.31.6.471.
    1. Pelletier J, Bruening W, Kashtan CE, Mauer SM, Manivel JC, Striegel JE, et al. Germline mutations in the Wilms’ tumor suppressor gene are associated with abnormal urogenital development in Denys-Drash syndrome. Cell. 1991;67(2):437–47. doi: 10.1016/0092-8674(91)90194-4.
    1. McCann-Crosby B, Roshanak M, Dietrich J, McCullough L, Sutton V, Austin E, et al. State of the art review in gonadal dysgenesis: challenges in diagnosis and management. Int J Pediatr Endcrinol. 2014;2014(1):4.
    1. Williams R, Al-Saadi R, Natrajan R, Mackay A, Chagtai T, Little S, et al. Molecular profiling reveals frequent gain of MYCN and anaplasia-specific loss of 4q and 14q in Wilms tumor. Genes Chromosomes Cancer. 2011;50(12):982–95.
    1. Natrajan R, Williams R, Hing S, Mackay A, Reis-Filho J, Fenwick K, et al. Array CGH profiling of favourable histology Wilms tumours reveals novel gains and losses associated with relapse. J Pathol. 2006
    1. Drake K, Ruteshouser E, Natrajan R, Harbor P, Wegert J, Gessler M, et al. Loss of heterozygosity at 2q37 in sporadic Wilms’ tumor: Putative role for miR-562. Cin Cancer Res. 2009
    1. Williams R, Chagtai T, Alcaide-German M, Apps J, Wegert J, Popov S, et al. Multiple mechanisms of MYCN dysregulation in Wilms tumour. Oncotarget. 2015;6(9):7232–43.
    1. Jones E, Stewart A, Stiller C, Douglas F, Bown N. Wilms tumor incidence in children with 2q terminal deletions: a cohort study. American Journal of Medical Genetics. 2011;155A(9):2221–3.
    1. Green DM, Breslow NE, Beckwith JB, Norkool P. Screening of children with hemihypertrophy, aniridia, and Beckwith-Wiedemann syndrome in patients with Wilms tumor: a report from the National Wilms Tumor Study. Medical and pediatric oncology. 1993;21(3):188.
    1. Choyke PL, Siegel MJ, Craft AW, Green DM, DeBaun MR. Screening for Wilms tumor in children with Beckwith-Wiedemann syndrome or idiopathic hemihypertrophy. Medical and Pediatric Oncology. 1999;32(3):196–200. doi: 10.1002/(SICI)1096-911X(199903)32:3<196::AID-MPO6>;2-9.
    1. Craft AW. Growth rate of Wilms’ tumour. The Lancet. 1999;354(9184):1127. doi: 10.1016/S0140-6736(05)76925-7.
    1. Beckwith JB. Children at increased risk for Wilms tumor: monitoring issues. J Pediatr. 1998;132(3 Pt 1):377–9.
    1. DeBaun MR, Tucker MA. Risk of cancer during the first four years of life in children from The Beckwith-Wiedemann Syndrome Registry. J Pediatr. 1998;132(3 Pt 1):398–400.
    1. Clericuzio CL, Chen E, McNeil DE, O’Connor T, Zackai EH, Medne L, et al. Serum alpha-fetoprotein screening for hepatoblastoma in children with Beckwith-Wiedemann syndrome or isolated hemihyperplasia. J Pediatr. 2003;143(2):270–2. doi: 10.1067/S0022-3476(03)00306-8.
    1. Trobaugh-Lotrario AD, Venkatramani R, Feusner JH. Hepatoblastoma in children with Beckwith-Wiedemann syndrome: does it warrant different treatment? J Pediatr Hematol Oncol. 2014;36(5):369–73. doi: 10.1097/MPH.0000000000000129.
    1. Chung EM, Cube R, Lewis RB, Conran RM. From the archives of the AFIP: Pediatric liver masses: radiologic-pathologic correlation part 1. Benign tumors Radiographics. 2010;30(3):801–26. doi: 10.1148/rg.303095173.
    1. Chung EM, Lattin GE, Jr, Cube R, Lewis RB, Marichal-Hernandez C, Shawhan R, et al. From the archives of the AFIP: Pediatric liver masses: radiologic-pathologic correlation. Part 2. Malignant tumors. Radiographics. 2011;31(2):483–507. doi: 10.1148/rg.312105201.
    1. Mussa A, Ferrero GB, Ceoloni B, Basso E, Chiesa N, De Crescenzo A, et al. Neonatal hepatoblastoma in a newborn with severe phenotype of Beckwith-Wiedemann syndrome. Eur J Pediatr. 2011;170(11):1407–11. doi: 10.1007/s00431-011-1455-0.
    1. Spector LG, Birch J. The epidemiology of hepatoblastoma. Pediatr Blood Cancer. 2012;59(5):776–9. doi: 10.1002/pbc.24215.
    1. Litten JB, Tomlinson GE. Liver tumors in children. Oncologist. 2008;13(7):812–20. doi: 10.1634/theoncologist.2008-0011.
    1. Clericuzio CL, Martin RA. Diagnostic criteria and tumor screening for individuals with isolated hemihyperplasia. Genetics in medicine : official journal of the American College of Medical Genetics. 2009;11(3):220–2. doi: 10.1097/GIM.0b013e31819436cf.
    1. Coakley J. Pediatric reference intervals for serum alpha-fetoprotein. Clin Chim Acta. 2012;413(1–2):352. doi: 10.1016/j.cca.2011.09.036.
    1. Teplick A, Kowalski M, Biegel JA, Nichols KE. Educational paper: Screening in cancer predisposition syndromes: guidelines for the general pediatrician. European Journal of Pediatrics. 2011;170(3):285–94. doi: 10.1007/s00431-010-1377-2.
    1. Weksberg R, Shuman C, Beckwith JB. Beckwith-Wiedemann syndrome. European Journal of Human Genetics. 2010;18(1):8–14. doi: 10.1038/ejhg.2009.106.
    1. Blair JI, Carachi R, Gupta R, Sim FG, McAllister EJ, Weston R. Plasma alpha fetoprotein reference ranges in infancy: effect of prematurity. Arch Dis Child. 1987;62(4):362–9.
    1. Everman DB, Shuman C, Dzolganovski B, O’Riordan MA, Weksberg R, Robin NH. Serum alpha-fetoprotein levels in Beckwith-Wiedemann syndrome. J Pediatr. 2000;137(1):123–7. doi: 10.1067/mpd.2000.106217.
    1. Mussa A, Ferrero GB. Screening Hepatoblastoma in Beckwith-Wiedemann Syndrome: A Complex Issue. J Pediatr Hematol Oncol. 2015;37(8):627. doi: 10.1097/MPH.0000000000000408.
    1. Zarate YA, Mena R, Martin LJ, Steele P, Tinkle BT, Hopkin RJ. Experience with hemihyperplasia and Beckwith-Wiedemann syndrome surveillance protocol. Am J Med Genet A. 2009;149A(8):1691–7. doi: 10.1002/ajmg.a.32966.
    1. Kassarjian A, Zurakowski D, Dubois J, Paltiel HJ, Fishman SJ, Burrows PE. Infantile hepatic hemangiomas: clinical and imaging findings and their correlation with therapy. AJR Am J Roentgenol. 2004;182(3):785–95. doi: 10.2214/ajr.182.3.1820785.
    1. Strobel D, Seitz K, Blank W, Schuler A, Dietrich C, von Herbay A, et al. Contrast-enhanced ultrasound for the characterization of focal liver lesions--diagnostic accuracy in clinical practice (DEGUM multicenter trial) Ultraschall Med. 2008;29(5):499–505. doi: 10.1055/s-2008-1027806.
    1. Hamilton TE, Shamberger RC. Wilms tumor: recent advances in clinical care and biology. Semin Pediatr Surg. 2012;21(1):15–20. doi: 10.1053/j.sempedsurg.2011.10.002.
    1. Owens CM, Brisse HJ, Olsen OE, Begent J, Smets AM. Bilateral disease and new trends in Wilms tumour. Pediatr Radiol. 2008;38(1):30–9. doi: 10.1007/s00247-007-0681-0.
    1. Perlman EJ. Pediatric renal tumors: practical updates for the pathologist. Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society. 2005;8(3):320.
    1. Alessandri JL, Cuillier F, Ramful D, Ernould S, Robin S, de Napoli-Cocci S, et al. Perlman syndrome: Report, prenatal findings and review. American Journal of Medical Genetics Part A. 2008;146A(19):2532–7. doi: 10.1002/ajmg.a.32391.
    1. Cottereau E, Mortemousque I, Moizard MP, Burglen L, Lacombe D, Gilbert-Dussardier B, et al. Phenotypic spectrum of Simpson-Golabi-Behmel syndrome in a series of 42 cases with a mutation in GPC3 and review of the literature. Am J Med Genet C Semin Med Genet. 2013;163C(2):92–105. doi: 10.1002/ajmg.c.31360.
    1. Cereda A, Carey JC. The trisomy 18 syndrome. Orphanet J Rare Dis. 2012;7:81. doi: 10.1186/1750-1172-7-81.
    1. Satge D, Nishi M, Sirvent N, Vekemans M. A tumor profile in Edwards syndrome (trisomy 18) Am J Med Genet C Semin Med Genet. 2016;172(3):296–306. doi: 10.1002/ajmg.c.31511.
    1. Breslow NE, Norris R, Norkool PA, Kang T, Beckwith JB, Perlman EJ, et al. Characteristics and outcomes of children with the Wilms tumor-Aniridia syndrome: a report from the National Wilms Tumor Study Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2003;21(24):4579.
    1. Mueller RF. The Denys-Drash syndrome. J Med Genet. 1994;31(6):471–7.
    1. McTaggart SJ, Algar E, Chow CW, Powell HR, Jones CL. Clinical spectrum of Denys-Drash and Frasier syndrome. Pediatr Nephrol. 2001;16(4):335–9.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅